Biohaven Pharmaceutical announces clinical trial collaboration with ADCS
Biohaven Pharmaceutical announced its clinical trial collaboration with the Alzheimer's Disease Cooperative Study, or ADCS. The ADCS is a leading Alzheimer's disease, or AD, clinical trials research consortium that receives major support from the U.S. National Institute on Aging, or NIA, a part of the US National Institutes of Health. The ADCS was developed to promote the discovery, development, and testing of new drugs for the treatment of AD. The ADCS includes a coordinating center housed at the University of California San Diego School of Medicine and a robust network of clinical research sites located at major academic medical centers and private clinics specializing in AD care and research throughout the United States and Canada. The ADCS has successfully completed the largest number of clinical trials in the AD field while also developing some of the important instruments for use within clinical trials. The ADCS has been undertaking the development efforts for this study over the last six months in partnership with Biohaven.